journal
MENU ▼
Read by QxMD icon Read
search

Journal of the National Cancer Institute

journal
https://www.readbyqxmd.com/read/29165716/targeting-bcr-abl-independent-tki-resistance-in-chronic-myeloid-leukemia-by-mtor-and-autophagy-inhibition
#1
Rebecca Mitchell, Lisa E M Hopcroft, Pablo Baquero, Elaine K Allan, Kay Hewit, Daniel James, Graham Hamilton, Arunima Mukhopadhyay, Jim O'Prey, Alan Hair, Junia V Melo, Edmond Chan, Kevin M Ryan, Véronique Maguer-Satta, Brian J Druker, Richard E Clark, Subir Mitra, Pawel Herzyk, Franck E Nicolini, Paolo Salomoni, G Vignir Helgason
Background: Imatinib and second-generation tyrosine kinase inhibitors (TKIs) nilotinib and dasatinib have statistically significantly improved the life expectancy of chronic myeloid leukemia (CML) patients; however, resistance to TKIs remains a major clinical challenge. Although ponatinib, a third-generation TKI, improves outcomes for patients with BCR-ABL-dependent mechanisms of resistance, including the T315I mutation, a proportion of patients may have or develop BCR-ABL-independent resistance and fail ponatinib treatment...
November 20, 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29165710/risk-of-soft-tissue-sarcoma-among-69-460-five-year-survivors-of-childhood-cancer-in-europe
#2
Chloe J Bright, Mike M Hawkins, David L Winter, Daniela Alessi, Rodrigue S Allodji, Francesca Bagnasco, Edit Bárdi, Andrea Bautz, Julianne Byrne, Elizabeth A M Feijen, Miranda M Fidler, Stanislaw Garwicz, Desiree Grabow, Thorgerdur Gudmundsdottir, Joyeeta Guha, Nadia Haddy, Momcilo Jankovic, Peter Kaatsch, Melanie Kaiser, Claudia E Kuehni, Helena Linge, Hilde Øfstaas, Cecile M Ronckers, Roderick Skinner, Jop C Teepen, Monica Terenziani, Giao Vu-Bezin, Finn Wesenberg, Thomas Wiebe, Carlotta Sacerdote, Zsuzsanna Jakab, Riccardo Haupt, Päivi Lähteenmäki, Lorna Zadravec Zaletel, Rahel Kuonen, Jeanette F Winther, Florent de Vathaire, Leontien C Kremer, Lars Hjorth, Raoul C Reulen
Background: Childhood cancer survivors are at risk of subsequent primary soft-tissue sarcomas (STS), but the risks of specific STS histological subtypes are unknown. We quantified the risk of STS histological subtypes after specific types of childhood cancer. Methods: We pooled data from 13 European cohorts, yielding a cohort of 69 460 five-year survivors of childhood cancer. Standardized incidence ratios (SIRs) and absolute excess risks (AERs) were calculated. Results: Overall, 301 STS developed compared with 19 expected (SIR = 15...
November 20, 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29165692/prognostic-value-of-clinical-vs-pathologic-stage-in-rectal-cancer-patients-receiving-neoadjuvant-therapy
#3
Daniel Delitto, Thomas J George, Tyler J Loftus, Peihua Qiu, George J Chang, Carmen J Allegra, William A Hall, Steven J Hughes, Sanda A Tan, Christiana M Shaw, Atif Iqbal
Background: Neoadjuvant chemoradiation is currently standard of care in stage II-III rectal cancer, resulting in tumor downstaging for patients with treatment-responsive disease. However, the prognosis of the downstaged patient remains controversial. This work critically analyzes the relative contribution of pre- and post-therapy staging to the anticipated survival of downstaged patients. Methods: The National Cancer Database (NCDB) was queried for patients with rectal cancer treated with transabdominal resection between 2004 and 2014...
November 20, 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29165687/investigation-of-the-relationship-between-radiation-dose-and-gene-mutations-and-fusions-in-post-chernobyl-thyroid-cancer
#4
Alexey A Efanov, Alina V Brenner, Tetiana I Bogdanova, Lindsey M Kelly, Pengyuan Liu, Mark P Little, Abigail I Wald, Maureen Hatch, Liudmyla Y Zurnadzy, Marina N Nikiforova, Vladimir Drozdovitch, Kiyohiko Mabuchi, Mykola D Tronko, Stephen J Chanock, Yuri E Nikiforov
Background: Exposure to ionizing radiation during childhood is a well-established risk factor for thyroid cancer. However, the genetic mechanisms of radiation-associated carcinogenesis remain not fully understood. Methods: In this study, we used targeted next-generation sequencing and RNA-Seq to study 65 papillary thyroid cancers (PTCs) from patients in the Ukrainian-American cohort with measurement-based iodine-131 (I-131) thyroid doses received as a result of the Chernobyl accident...
November 18, 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29165667/braf-v600e-mutation-assisted-risk-stratification-of-solitary-intrathyroidal-papillary-thyroid-cancer-for-precision-treatment
#5
Yueye Huang, Shen Qu, Guangwu Zhu, Fei Wang, Rengyun Liu, Xiaopei Shen, David Viola, Rossella Elisei, Efisio Puxeddu, Laura Fugazzola, Carla Colombo, Barbara Jarzab, Agnieszka Czarniecka, Alfred K Lam, Caterina Mian, Federica Vianello, Linwah Yip, Garcilaso Riesco-Eizaguirre, Pilar Santisteban, Christine J O'Neill, Mingzhao Xing, Mark S Sywak, Roderick Clifton-Bligh, Bela Bendlova, Vlasta Sýkorová
Background: Precise risk stratification-based treatment of solitary intrathyroidal papillary thyroid cancer (SI-PTC) that is larger than 1.0 cm and 4.0 cm or less is undefined. Methods: A genetic-clinical risk study was performed on BRAF V600E in 955 patients (768 women and 187 men) with SI-PTC, with median age of 46 years and median clinical follow-up time of 64 months at 11 medical centers in six countries. The chi-square test or, for analyses with small numbers, Fisher's exact test was performed to compare recurrence rates...
November 18, 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29165658/thyroid-cancer-is-it-all-in-the-genes
#6
Electron Kebebew
No abstract text is available yet for this article.
November 18, 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29155997/immune-activation-and-benefit-from-avelumab-in-ebv-positive-gastric-cancer
#7
Anshuman Panda, Janice M Mehnert, Kim M Hirshfield, Greg Riedlinger, Sherri Damare, Tracie Saunders, Michael Kane, Levi Sokol, Mark N Stein, Elizabeth Poplin, Lorna Rodriguez-Rodriguez, Ann W Silk, Joseph Aisner, Nancy Chan, Jyoti Malhotra, Melissa Frankel, Howard L Kaufman, Siraj Ali, Jeffrey S Ross, Eileen P White, Gyan Bhanot, Shridar Ganesan
Response to immune checkpoint therapy can be associated with a high mutation burden, but other mechanisms are also likely to be important. We identified a patient with metastatic gastric cancer with meaningful clinical benefit from treatment with the anti-programmed death-ligand 1 (PD-L1) antibody avelumab. This tumor showed no evidence of high mutation burden or mismatch repair defect but was strongly positive for presence of Epstein-Barr virus (EBV) encoded RNA. Analysis of The Cancer Genome Atlas gastric cancer data (25 EBV+, 80 microsatellite-instable [MSI], 310 microsatellite-stable [MSS]) showed that EBV-positive tumors were MSS...
November 15, 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29155972/screening-guideline-for-cervical-cancer-recommends-against-human-papillomavirus-pap-cotesting
#8
Anna Azvolinsky
No abstract text is available yet for this article.
November 15, 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29155953/max-mutations-in-endometrial-cancer-clinicopathologic-associations-and-recurrent-max-p-his28arg-functional-characterization
#9
Christopher J Walker, Craig M Rush, Paola Dama, Matthew J O'Hern, Casey M Cosgrove, Jessica L Gillespie, Roman A Zingarelli, Blair Smith, Maggie E Stein, David G Mutch, Reena Shakya, Chia-Wen Chang, Karuppaiyah Selvendiran, Jonathan W Song, David E Cohn, Paul J Goodfellow
Background: Genomic studies have revealed that multiple genes are mutated at varying frequency in endometrial cancer (EC); however, the relevance of many of these mutations is poorly understood. An EC-specific recurrent mutation in the MAX transcription factor p.His28Arg was recently discovered. We sought to assess the functional consequences of this hotspot mutation and determine its association with cancer-relevant phenotypes. Methods: MAX was sequenced in 509 endometrioid ECs, and associations between mutation status and clinicopathologic features were assessed...
November 15, 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29155945/glyphosate-use-and-cancer-incidence-in-the-agricultural-health-study-an-epidemiologic-perspective
#10
Elizabeth M Ward
No abstract text is available yet for this article.
November 15, 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29155933/pd-l1-antibodies-for-ebv-positive-gastric-cancer-going-beyond-pd-l1-expression-and-microsatellite-instability
#11
Khaldoun Almhanna, Scott Antonia
No abstract text is available yet for this article.
November 15, 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29145648/relative-performance-of-hpv-and-cytology-components-of-cotesting-in-cervical-screening
#12
Mark Schiffman, Walter K Kinney, Li C Cheung, Julia C Gage, Barbara Fetterman, Nancy E Poitras, Thomas S Lorey, Nicolas Wentzensen, Brian Befano, John Schussler, Hormuzd A Katki, Philip E Castle
Background: The main goal of cervical screening programs is to detect and treat precancer before cancer develops. Human papillomavirus (HPV) testing is more sensitive than cytology for detecting precancer. However, reports of rare HPV-negative, cytology-positive cancers are motivating continued use of both tests (cotesting) despite increased testing costs. Methods: We quantified the detection of cervical precancer and cancer by cotesting compared with HPV testing alone at Kaiser Permanente Northern California (KPNC), where 1 208 710 women age 30 years and older have undergone triennial cervical cotesting since 2003...
November 14, 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29136183/glyphosate-use-and-cancer-incidence-in-the-agricultural-health-study
#13
Gabriella Andreotti, Stella Koutros, Jonathan N Hofmann, Dale P Sandler, Jay H Lubin, Charles F Lynch, Catherine C Lerro, Anneclaire J De Roos, Christine G Parks, Michael C Alavanja, Debra T Silverman, Laura E Beane Freeman
Background: Glyphosate is the most commonly used herbicide worldwide, with both residential and agricultural uses. In 2015, the International Agency for Research on Cancer classified glyphosate as "probably carcinogenic to humans," noting strong mechanistic evidence and positive associations for non-Hodgkin lymphoma (NHL) in some epidemiologic studies. A previous evaluation in the Agricultural Health Study (AHS) with follow-up through 2001 found no statistically significant associations with glyphosate use and cancer at any site...
November 9, 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29121329/response
#14
Trevor J Bledsoe, Henry S Park, John M Stahl, Wendell G Yarbrough, Barbara A Burtness, Roy H Decker, Zain A Husain
No abstract text is available yet for this article.
November 7, 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29121261/re-hypofractionated-radiotherapy-for-patients-with-early-stage-glottic-cancer-patterns-of-care-and-survival
#15
Jens Overgaard
No abstract text is available yet for this article.
November 7, 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29126314/cost-effectiveness-analysis-of-nivolumab-for-treatment-of-platinum-resistant-recurrent-or-metastatic-squamous-cell-carcinoma-of-the-head-and-neck
#16
Kathryn R Tringale, Kate T Carroll, Kaveh Zakeri, Assuntina G Sacco, Linda Barnachea, James D Murphy
Background: The CheckMate 141 trial found that nivolumab improved survival for patients with recurrent or metastatic head and neck cancer (HNC). Despite the improved survival, nivolumab is much more expensive than standard therapies. This study assesses the cost-effectiveness of nivolumab for the treatment of HNC. Methods: We constructed a Markov model to simulate treatment with nivolumab or standard single-agent therapy for patients with recurrent or metastatic platinum-refractory HNC...
November 3, 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29126306/the-future-of-radiobiology
#17
David G Kirsch, Max Diehn, Aparna H Kesarwala, Amit Maity, Meredith A Morgan, Julie K Schwarz, Robert Bristow, Sandra Demaria, Iris Eke, Robert J Griffin, Daphne Haas-Kogan, Geoff S Higgins, Alec C Kimmelman, Randall J Kimple, Isabelle M Lombaert, Li Ma, Brian Marples, Frank Pajonk, Catherine C Park, Dörthe Schaue, Eric J Bernhard
Innovation and progress in radiation oncology depend on discovery and insights realized through research in radiation biology. Radiobiology research has led to fundamental scientific insights, from the discovery of stem/progenitor cells to the definition of signal transduction pathways activated by ionizing radiation that are now recognized as integral to the DNA damage response (DDR). Radiobiological discoveries are guiding clinical trials that test radiation therapy combined with inhibitors of the DDR kinases DNA-dependent protein kinase (DNA-PK), ataxia telangiectasia mutated (ATM), ataxia telangiectasia related (ATR), and immune or cell cycle checkpoint inhibitors...
November 3, 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29126281/retuning-the-radio-in-radiobiology
#18
Steven J Chmura, Philip P Connell, Ralph R Weichselbaum
No abstract text is available yet for this article.
November 3, 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29106610/updates-to-the-national-cancer-institute-s-pdq-information-from-recently-published-oncology-research
#19
(no author information available yet)
No abstract text is available yet for this article.
November 2, 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29106609/first-chimeric-antigen-receptor-t-cell-therapy-approved
#20
Vicki Brower
No abstract text is available yet for this article.
November 2, 2017: Journal of the National Cancer Institute
journal
journal
20157
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"